What it sells
Using CRISPR to find treatments for cancer and inflammation
Business model breakdown
Buyer: who owns the budget?
UnverifiedLarge pharma partners licensing target discovery (e.g. AstraZeneca).
Economics: what it saves and how it charges
Pharma partnership deals; press lists a potential $555m AstraZeneca deal (October 6, 2025).
Distribution: how it reaches customers
UnverifiedPartnership / business development; no product sales.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.